Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
12
|
| pubmed:dateCreated |
1992-5-28
|
| pubmed:abstractText |
We compared the efficacy of a long-duration (3-week) therapy of vancomycin, fleroxacin, fleroxacin plus rifampin, and vancomycin plus fleroxacin and rifampin in a recently developed rat model of chronic staphylococcal foreign-body infection. Subcutaneous tissue cages containing polymethylmethacrylate coverslips were infected with 1 x 10(5) to 5 x 10(5) CFU of methicillin-resistant Staphylococcus aureus. Three weeks later, a quantitative culturing of the fluid that had accumulated in the cages was done (mean, 6.72 log10 CFU/ml; n = 110) and treatment was initiated after randomization. The CFUs in the cage fluid were counted on days 11 and 22 and 1 week after the termination of treatment; in addition, a final culture of coverslips (surface-bound microorganisms) was performed. The three-drug therapy was significantly superior to the other treatments on day 11 (a 5.16 log10 decrease of bacterial counts versus a 2.12 log10 to 2.94 log10 decrease for vancomycin, fleroxacin, and fleroxacin plus rifampin; P less than 0.01). On day 22, count decreases were 4.16 log10 for vancomycin, 4.91 log10 for fleroxacin (vancomycin versus fleroxacin, not significant), 6.14 log10 for two-drug therapy, and 6.34 log10 for three-drug therapy (vancomycin-fleroxacin-rifampin versus fleroxacin-rifampin, not significant; fleroxacin-rifampin versus monotherapies, P less than 0.01); the numbers of CFU in most cage fluids were under the detection limit (20 CFU/ml) in combination groups. One week after the end of treatment, 92% of fluids and coverslips (detection limit, 1 CFU) were culture negative with tritherapy, 88% of fluids and 41% of coverslips were negative with bitherapy, and less than 12% of fluids and coverslips were negative with single drugs (for coverslips, P was <0.01 for vancomycin-fleroxacin-rifampin versus fleroxacin-rifampin and P was <0.001 for fleroxacin-rifampin versus the monotherapies). No mutants resistant to rifampin or fleroxacin were detected. In conclusion, antimicrobial combinations were highly effective and superior to single drugs in treating a chronic staphylococcal foreign-body infection for 3 weeks. The three-drug therapy decreased bacterial counts more rapidly than the two-drug therapy under study and appeared to be curative in most cases.
|
| pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/1810196-1903801,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1810196-1984473,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1810196-2037793,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1810196-2128441,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1810196-2222100,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1810196-2393259,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1810196-2499251,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1810196-2572799,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1810196-2712546,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1810196-2802547,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1810196-3133348,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1810196-3182460,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1810196-3290183,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1810196-3356621,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1810196-3470281,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1810196-3481244,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1810196-3566245,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1810196-3578332,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1810196-3707110,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1810196-3844314,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1810196-3980330,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1810196-6879000,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1810196-7119479
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
0066-4804
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
35
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
2611-6
|
| pubmed:dateRevised |
2009-11-18
|
| pubmed:meshHeading |
pubmed-meshheading:1810196-Animals,
pubmed-meshheading:1810196-Cells, Cultured,
pubmed-meshheading:1810196-Chronic Disease,
pubmed-meshheading:1810196-Drug Interactions,
pubmed-meshheading:1810196-Drug Therapy, Combination,
pubmed-meshheading:1810196-Fleroxacin,
pubmed-meshheading:1810196-Foreign-Body Reaction,
pubmed-meshheading:1810196-Methicillin Resistance,
pubmed-meshheading:1810196-Microbial Sensitivity Tests,
pubmed-meshheading:1810196-Rats,
pubmed-meshheading:1810196-Rats, Inbred Strains,
pubmed-meshheading:1810196-Rifampin,
pubmed-meshheading:1810196-Staphylococcal Infections,
pubmed-meshheading:1810196-Staphylococcus aureus,
pubmed-meshheading:1810196-Vancomycin
|
| pubmed:year |
1991
|
| pubmed:articleTitle |
Successful therapy of experimental chronic foreign-body infection due to methicillin-resistant Staphylococcus aureus by antimicrobial combinations.
|
| pubmed:affiliation |
Division of Infectious Diseases, University Hospital, Geneva, Switzerland.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|